Skip to content

Metformin showed a modest BMI advantage in youth taking antipsychotics

Adding metformin to lifestyle guidance favored the BMI outcome, while gastrointestinal side effects were more common.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

In youth taking antipsychotics who had bipolar spectrum disorders and overweight or obesity, adding metformin to lifestyle guidance produced a modest advantage in the BMI outcome. The reported effect was smaller at the later assessment. Gastrointestinal side effects were more common, so the result involves a tolerability tradeoff.

Keep in mind

The trial was unblinded, and some follow-up data were missing. This abstract-based account cannot provide an absolute weight difference in kilograms.

THE NUMBERS, WITH CONTEXT

What researchers found

0·26 (95% CI 0·15-0·37)

Standardized between-group effect on BMI Z-score change

Metformin plus LIFE versus LIFE alone at 6 months; p<0·0001.

0·11 (95% CI 0·00-0·22)

Standardized between-group effect on BMI Z-score change

Metformin plus LIFE versus LIFE alone at 24 months; p=0·047.

Lancet Psychiatry, 2025 · Original source ↓

Understanding the effect sizes

BMI Z-score adjusts BMI for age and sex. The reported 0·26 and 0·11 are standardized between-group effects favoring metformin, rather than direct changes of those amounts in BMI Z-score units or percentages of body weight lost.

Safety findings

The groups did not differ significantly on the reported suicide-related measure during treatment. A nonsignificant result does not establish equal safety, and the abstract separately reports more gastrointestinal adverse events with metformin.

CHECK THE ORIGINAL

The original publication

Metformin for overweight and obese children and adolescents with bipolar spectrum and related mood disorders treated with second-generation antipsychotics: a randomised, pragmatic trial.

DelBello MP, Welge JA, Klein CC et al.
Lancet Psychiatry · 2025

PubMed ID
41233082
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.